Full-Year Data Back TYK2 Blocker in Psoriatic Arthritis

By News Health
32 minutes Ago

(MedPage Today) — CHICAGO — Plaque psoriasis drug deucravacitinib (Sotyktu) now looks likely to win a psoriatic arthritis (PsA) indication in the near future, with results after 1 year reported here from one of its key phase III trials.
Further…

Source link : https://www.medpagetoday.com/meetingcoverage/acr/118248

Author :

Publish date : 2025-10-31 13:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

The Swiss Wrote the Psychedelic Playbook; Now Europe Follows

Calculator May Predict Heart Risks After Breast Cancer

The New Scientist Book Club's verdict on Our Brains, Our Selves: A mix of praise and misgivings

Exercise: A Way to Reduce Depression in Teens With T2D?

New Scientist Book Club: Read an extract from sci-fi novel Every Version of You by Grace Chan

Late-Pregnancy Loss Often Strikes Even Low-Risk Pregnancies